Johnson & Johnson’s Janssen unit halted enrollment in a Phase I clinical trial of Essa Pharma’s prostate cancer drug, EPI-7386. After the news was made public, Essa’s shares dropped 26% to $3.25. (MarketWatch)

By the next RSV season, the U.S. may have its first vaccine, experts predicted. In a recent clinical trial, an antibody shot was 75% effective at heading off RSV infections that required medical attention. (CNN)

Battling cholera, Lebanon received its first vaccines as well as some sharp words from France. The World Health Organization has linked cholera’s comeback in Lebanon to an outbreak in neighboring Syria, to where it had spread from Afghanistan via Iran and Iraq. (Reuters)

China blocked GSK from its bulk-buy drug program until April 2024, citing quality issues with the drugmaker’s prostate drug Avodart. The volume-based procurement program aims to increase use of generic drugs, and entails pharma companies selling drugs in bulk at hospitals. (Reuters

One in 10 U.S. adults over the age of 65 has dementia, according to a new study published in JAMA Neurology. The researchers noted that non-white people have often been “excluded from dementia research but are at higher risk of development cognitive impairment” due to systemic racism and income inequality. (The Washington Post)